Connect Biopharma(NASDAQ) CNTB

Current Price$2.16

Market Cap$134.74M

Since IPO (2025)+8%

5 Year-92%

1 Year-9%

1 Month+1%

Connect Biopharma last closing stock price
Metric	Price	Date
Last close	USD 2.14	2026-07-24

Connect Biopharma stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-10.08%	USD 2.38	2026-07-17
1 month	+0.94%	USD 2.12	2026-06-24
3 month	-15.08%	USD 2.52	2026-04-24
Year to date	-24.11%	USD 2.82	2025-12-31
1 year	-8.94%	USD 2.35	2025-07-24
3 year	+107.77%	USD 1.03	2023-07-25
5 year	-91.77%	USD 26.00	2021-07-23
Since inception	+7.54%	USD 1.99	2025-09-03

Connect Biopharma Financials at a Glance

Market Cap

$134.74M

Revenue (TTM)

$24.86M

Net Income (TTM)

-$22.07M

EPS (TTM)

-$1.15

P/E Ratio

-1.85

Dividend

$0.00

Beta (Volatility)

0.53 (Low)

Dividend

$0.00

Beta (Volatility)

0.53 (Low)

Price

$2.16

Volume

4,731

Open

$2.19

Price

$2.16

Volume

4,731

Open

$2.19

Previous Close

$2.16

Daily Range

$2.10 - $2.19

52-Week Range

$1.23 - $3.82

Estimated Earnings Date

Aug 12, 2026

Dividend

$0.00

Beta (Volatility)

0.53 (Low)

Price

$2.16

Volume

4,731

Open

$2.19

Previous Close

$2.16

Daily Range

$2.10 - $2.19

52-Week Range

$1.23 - $3.82

Estimated Earnings Date

Aug 12, 2026

CNTB News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Connect Biopharma

Connect Biopharma develops medicines for people with immune system diseases. Its main drugs aim to help those with asthma, eczema, and chronic itching. These treatments target the body’s immune response to reduce inflammation and discomfort.

What’s in the Medicine Cabinet?

Rademikibart (CBP-201): Antibody drug for asthma, eczema, and chronic sinus issues; all 2025 recognized revenue from licensing and collaboration agreements related to rademikibart.
CBP-307: Oral drug in trials for autoimmune diseases, targeting immune cell movement.
CBP-174: Early-stage oral drug for chronic itch linked to skin inflammation.
CBP-233: Preclinical antibody for allergic inflammation, not yet in human trials.

Growth Spurts and Global Moves

Signed exclusive license with Simcere Pharmaceutical for rademikibart in Greater China in 2023.
Launched two Phase 2 trials for rademikibart in asthma and COPD in May 2025.
Relocated headquarters to San Diego, USA, in February 2025; maintains operations in Taicang, China.
Received $26 million in milestone payments from Simcere in 2024; revenue dropped in 2025 as payments ended.
Raised $20.2 million in a private placement in March 2026 to support operations.

Why Connect Biopharma Stands Out

The company focuses on immune system pathways that drive inflammation, using both antibody and small molecule drugs. Its partnership with Simcere opens access to the large Chinese market and provides milestone payments. A global patent portfolio supports its pipeline and future commercialization efforts.

Five Things You Need to Know

2025 revenue was $48,000, down 99.8% from $24 million in 2024.
Net loss was $13 million in 2025, compared to $7 million profit in 2024.
All 2025 revenue came from Simcere collaboration; no product sales yet.
Cash and short-term investments totaled $44.3 million at end of 2025.
Connect has 62 employees and no long-term debt as of December 2025.

Bottom Line

Connect Biopharma is a clinical-stage drug developer focused on immune diseases, with a single major partnership driving recent revenue. The company faces ongoing losses but maintains a global presence and a pipeline of new treatments.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Barry D. Quart, PharmD

Website

www.connectbiopharm.com

Headquarters

San Diego, CA 215400, US

CNTB Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-60312.50%

Net Income Margin

-58350.00%

Return on Equity

-49.43%

Return on Capital

-136.10%

Return on Assets

-49.95%

Earnings Yield

-54.05%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$134.74M

Shares Outstanding

62.96M

Volume

4.73K

Avg. Volume

370.27K

Financials (TTM)

Gross Profit

$24.86M

Operating Income

-$24.92M

EBITDA

-$21.16M

Operating Cash Flow

-$47.39M

Capital Expenditure

-$1.07M

Free Cash Flow

-$48.46M

Cash & ST Invst.

$44.34M

Total Debt

$690.00K

Connect Biopharma Performance Analysis

Connect Biopharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 0	N/A
2023	2023-12-31	USD 0	N/A
2024	2024-12-31	USD 26,033,000	N/A
2025	2025-12-31	USD 64,000	-99.8%

Connect Biopharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2024-06-30	N/A
Q4	2024-12-31	-97.1%
Q2	2025-06-30	-93.1%
Q4	2025-12-31	-100.0%

Connect Biopharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -2.15	-44.6%
2023	2023-12-31	USD -1.13	-47.6%
2024	2024-12-31	USD -0.28	-74.9%
2025	2025-12-31	USD -1.00	252.2%

Connect Biopharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2024-06-30	126.9%
Q4	2024-12-31	-400.0%
Q2	2025-06-30	45.2%
Q4	2025-12-31	-17.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$134.74M

N/A

Market Cap/Employee

$2.11M

N/A

Employees

N/A

Net Income

-$15.11M

+52.2%

EBITDA

-$14.90M

+57.8%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Total Cash

$44.34M

-62.5%

Total Debt

$690.00K

+48.4%

Accounts Receivable

$161.00K

-54.1%

Inventory

$0.00

N/A

Long Term Debt

$368.00K

+104.4%

Short Term Debt

$322.00K

+13.0%

Return on Assets

-49.95%

N/A

Return on Invested Capital

-68.18%

N/A

Free Cash Flow

-$11.27M

+33.1%

Operating Cash Flow

-$11.25M

+33.2%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

IFRXInflaRx N.V.

IFRXInflaRx N.V.$1.74+0.58%

KLRSKalaris Therapeutics Inc

KLRSKalaris Therapeutics Inc$3.73-4.85%

IMAImageneBio Inc

IMAImageneBio Inc$5.59+0.36%

CNTXContext Therapeutics Inc.

CNTXContext Therapeutics Inc.$0.61+3.68%

STROSutro Biopharma, Inc.

STROSutro Biopharma, Inc.$22.88-3.05%

MGXMetagenomi, Inc. Common Stock

MGXMetagenomi, Inc. Common Stock$1.21-1.23%

ARTVArtiva Biotherapeutics, Inc.

ARTVArtiva Biotherapeutics, Inc.$10.03-0.99%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.42-0.04%

ONDSOndas

ONDSOndas$7.80-0.02%

SOFISoFi Technologies

SOFISoFi Technologies$16.46-0.01%

TAT&T

TAT&T$24.13+0.05%

FFord Motor Company

FFord Motor Company$14.37+0.02%

CLFCleveland-Cliffs

CLFCleveland-Cliffs$11.93+0.09%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$64.00-0.03%

Questions About CNTB

What is the current price of Connect Biopharma?

Connect Biopharma is trading at $2.16 per share.

What is the 52-week range for Connect Biopharma?

Over the past 52 weeks, Connect Biopharma has traded between $1.23 and $3.82.

How much debt does Connect Biopharma have?

As of the most recent reporting period, Connect Biopharma reported total debt of $693.00K.

How much cash does Connect Biopharma have on hand?

Connect Biopharma reported $46.03M in cash and cash equivalents in its most recent financial results.

What is Connect Biopharma’s dividend yield?

Connect Biopharma does not currently have a dividend yield.

Connect Biopharma(NASDAQ) CNTB

Connect Biopharma Financials at a Glance

CNTB News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Connect Biopharma

What’s in the Medicine Cabinet?

Growth Spurts and Global Moves

Why Connect Biopharma Stands Out

Five Things You Need to Know

Bottom Line

CNTB Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Connect Biopharma Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About CNTB

What is the current price of Connect Biopharma?

What is the 52-week range for Connect Biopharma?

How much debt does Connect Biopharma have?

How much cash does Connect Biopharma have on hand?

What is Connect Biopharma’s dividend yield?

Premium Investing Services